Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Modulation of the Biophysical Properties of Bifunctional Antibodies as a Strategy for Mitigating Poor Pharmacokinetics.

Datta-Mannan A, Brown RM, Fitchett J, Heng AR, Balasubramaniam D, Pereira J, Croy JE.

Biochemistry. 2019 Jul 16;58(28):3116-3132. doi: 10.1021/acs.biochem.9b00074. Epub 2019 Jul 8.

PMID:
31241304
2.

Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides.

Datta-Mannan A.

Drug Metab Dispos. 2019 Oct;47(10):1100-1110. doi: 10.1124/dmd.119.086488. Epub 2019 May 1.

PMID:
31043438
3.

The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.

Datta-Mannan A, Choi H, Stokell D, Tang J, Murphy A, Wrobleski A, Feng Y.

AAPS J. 2018 Sep 25;20(6):103. doi: 10.1208/s12248-018-0263-0.

PMID:
30255287
4.

Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.

Datta-Mannan A, Boyles J, Huang L, Jin ZY, Peariso A, Murphy AT, Ellis B, Douglass N, Norouziyan-Cooper F, Witcher DR.

Biotechnol J. 2019 Mar;14(3):e1800007. doi: 10.1002/biot.201800007. Epub 2018 Jun 26.

PMID:
29802766
5.

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ.

MAbs. 2016 Jul;8(5):969-82. doi: 10.1080/19420862.2016.1178435.

6.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ.

Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Review.

PMID:
26669328
7.

Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc-Based Biotherapeutics.

Datta-Mannan A, Huang L, Pereira J, Yaden B, Korytko A, Croy JE.

Drug Metab Dispos. 2015 Dec;43(12):1882-90. doi: 10.1124/dmd.115.064519. Epub 2015 Sep 9.

PMID:
26354950
8.

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ.

MAbs. 2015;7(6):1084-93. doi: 10.1080/19420862.2015.1075109. Epub 2015 Sep 4.

9.

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ.

MAbs. 2015;7(3):483-93. doi: 10.1080/19420862.2015.1016696.

10.

Application of FcRn binding assays to guide mAb development.

Datta-Mannan A, Wroblewski VJ.

Drug Metab Dispos. 2014 Nov;42(11):1867-72. doi: 10.1124/dmd.114.059089. Epub 2014 Jul 14. Review.

PMID:
25024401
11.

Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice.

Yaden BC, Wang YX, Wilson JM, Culver AE, Milner A, Datta-Mannan A, Shetler P, Croy JE, Dai G, Krishnan V.

Am J Pathol. 2014 Apr;184(4):1152-66. doi: 10.1016/j.ajpath.2013.12.029.

PMID:
24655377
12.

Follistatin: a novel therapeutic for the improvement of muscle regeneration.

Yaden BC, Croy JE, Wang Y, Wilson JM, Datta-Mannan A, Shetler P, Milner A, Bryant HU, Andrews J, Dai G, Krishnan V.

J Pharmacol Exp Ther. 2014 May;349(2):355-71. doi: 10.1124/jpet.113.211169. Epub 2014 Mar 13.

PMID:
24627466
13.

Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin.

Beidler CB, Petrovan RJ, Conner EM, Boyles JS, Yang DD, Harlan SM, Chu S, Ellis B, Datta-Mannan A, Johnson RL, Stauber A, Witcher DR, Breyer MD, Heuer JG.

J Pharmacol Exp Ther. 2014 May;349(2):330-43. doi: 10.1124/jpet.113.210765. Epub 2014 Feb 11.

PMID:
24518034
14.

An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential.

Datta-Mannan A, Yaden B, Krishnan V, Jones BE, Croy JE.

J Pharmacol Exp Ther. 2013 Mar;344(3):616-23. doi: 10.1124/jpet.112.201491. Epub 2012 Dec 17. Erratum in: J Pharmacol Exp Ther. 2015 Aug;354(2):238.

PMID:
23249626
15.

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.

Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ.

Drug Metab Dispos. 2012 Aug;40(8):1545-55. doi: 10.1124/dmd.112.045864. Epub 2012 May 14.

PMID:
22584253
16.

Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ.

MAbs. 2012 Mar-Apr;4(2):267-73. doi: 10.4161/mabs.4.2.19364. Epub 2012 Mar 1.

17.

Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.

Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW.

Mol Biol Cell. 2008 Dec;19(12):5490-505. doi: 10.1091/mbc.E07-02-0101. Epub 2008 Oct 8.

18.

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ.

J Biol Chem. 2007 Jan 19;282(3):1709-17. Epub 2006 Nov 29.

19.

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ.

Drug Metab Dispos. 2007 Jan;35(1):86-94. Epub 2006 Oct 18.

PMID:
17050651
20.
21.

Specificity determinants for chemokine recognition identified using eotaxin-MCP-1 chimeras.

Mayer MR, Parody TR, Datta-Mannan A, Stone MJ.

FEBS Lett. 2004 Jul 30;571(1-3):166-70.

Supplemental Content

Loading ...
Support Center